Ardelyx's (ARDX) Shares Plunge as Tenapanor's Deficiencies Identified by FDA 'Take Approval Off the Table'

Ardelyx, Inc (ARDX) PT Lowered to $6.50 at Ladenburg Thalmann

Ladenburg Thalmann analyst Matthew Kaplan lowered the price target on Ardelyx, Inc (NASDAQ: ARDX) to $6.50 (from $15.00) while maintaining a Buy rating.... More

UPDATE: Wedbush Downgrades Ardelyx, Inc (ARDX) to Neutral

(Updated - July 20, 2021 6:23 AM EDT)

Wedbush analyst Laura Chico downgraded Ardelyx, Inc (NASDAQ: ARDX) from Outperform to Neutral with a price target of $3.00 (from $14.00).

The analyst comments "ARDX announced an FDA letter identifying deficiencies in the tenapanor NDA that will preclude further labeling discussions.... More

Piper Sandler Downgrades Ardelyx, Inc (ARDX) to Neutral

Piper Sandler analyst Christopher Raymond downgraded Ardelyx, Inc (NASDAQ: ARDX) from Overweight to Neutral with a price target of $4.00 (from $14.00).

For an analyst ratings summary and ratings history on Ardelyx, Inc click here. For more ratings news on Ardelyx, Inc click here.

Shares of Ardelyx, Inc closed at $7.70 yesterday.

After-Hours Stock Movers 07/19: (AMRX) (CCK) (IBM) Higher; (ARDX) (RCUS) (PPG) Lower (more...)

After-Hours Stock Movers

Ardelyx, Inc. (Nasdaq: ARDX) 69% LOWER; received a letter from the U.S. Food and Drug Administration (the "FDA") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application ("NDA") for the control of serum phosphorus in adult patients with chronic kidney disease ("CKD") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The... More

Ardelyx (ARDX) to Resume Trading at 4:30 p.m.

Ardelyx (NASDAQ: ARDX) to Resume Trading at 4:30 p.m.

Ardelyx (ARDX) says FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments for Tenapanor at this time

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it received a letter from the U.S. Food and Drug Administration (the "FDA") on July 13, 2021, stating that, as part of its ongoing review of the company's New... More

Ardelyx (ARDX) Halted, News Pending

Ardelyx (NASDAQ: ARDX) Halted, News Pending